CARD11 and lymphoma: CARD11, which is associated with lack of response to ibrutinib,17 encodes a scaffold protein required for BCR activation of NF‐κB signaling and implicated in lymphoma tumorigenesis,46 indicating that resistance to ibrutinib may be more closely linked to NF‐kB‐related pathways in the tumor.